These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27272237)

  • 61. Voglibose administration regulates body weight and energy intake in high fat-induced obese mice.
    Do HJ; Jin T; Chung JH; Hwang JW; Shin MJ
    Biochem Biophys Res Commun; 2014 Jan; 443(3):1110-7. PubMed ID: 24388987
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.
    Gorden P; Park JY
    Arch Physiol Biochem; 2006 Apr; 112(2):114-8. PubMed ID: 16931453
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rationale for leptin-replacement therapy for severe lipodystrophy.
    Oral EA; Chan JL
    Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Leptin treatment has vasculo-protective effects in lipodystrophic mice.
    Stürzebecher PE; Kralisch S; Schubert MR; Filipova V; Hoffmann A; Oliveira F; Sheikh BN; Blüher M; Kogel A; Scholz M; Kokot KE; Erbe S; Kneuer JM; Ebert T; Fasshauer M; Miehle K; Laufs U; Tönjes A; Boeckel JN
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2110374119. PubMed ID: 36161905
    [TBL] [Abstract][Full Text] [Related]  

  • 65. NRG1-Fc improves metabolic health via dual hepatic and central action.
    Zhang P; Kuang H; He Y; Idiga SO; Li S; Chen Z; Yang Z; Cai X; Zhang K; Potthoff MJ; Xu Y; Lin JD
    JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515030
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dihydrocapsiate improved age-associated impairments in mice by increasing energy expenditure.
    Ohyama K; Suzuki K
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E586-E597. PubMed ID: 28811294
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906.
    Tajima K; Shirakawa J; Togashi Y; Yamazaki S; Okuyama T; Kyohara M; Konishi H; Terauchi Y
    Sci Rep; 2017 Jun; 7(1):4119. PubMed ID: 28646158
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Metreleptin treatment of non-HIV lipodystrophy syndromes.
    Chevalier B; Lemaitre M; Leguier L; Mapihan KL; Douillard C; Jannin A; Espiard S; Vantyghem MC
    Presse Med; 2021 Nov; 50(3):104070. PubMed ID: 34571177
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy.
    Muniyappa R; Brown RJ; Mari A; Joseph J; Warren MA; Cochran EK; Skarulis MC; Gorden P
    Diabetes Care; 2014 Apr; 37(4):1101-7. PubMed ID: 24496806
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.
    Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ
    F1000Res; 2019; 8():. PubMed ID: 31656583
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Progranulin is increased in human and murine lipodystrophy.
    Miehle K; Ebert T; Kralisch S; Hoffmann A; Kratzsch J; Schlögl H; Stumvoll M; Fasshauer M
    Diabetes Res Clin Pract; 2016 Oct; 120():1-7. PubMed ID: 27497155
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Health risks of lipodystrophy and abdominal fat accumulation: therapeutic possibilities with leptin and human growth hormone.
    Van Gaal LF; Mertens IL; Abrams PJ
    Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S4-9. PubMed ID: 12914718
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.
    Moon HS; Dalamaga M; Kim SY; Polyzos SA; Hamnvik OP; Magkos F; Paruthi J; Mantzoros CS
    Endocr Rev; 2013 Jun; 34(3):377-412. PubMed ID: 23475416
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Lipodystrophy. Mechanisms, clinical presentation, therapy].
    Miehle K; Stumvoll M; Fasshauer M
    Internist (Berl); 2011 Apr; 52(4):362, 364-6, 368-70 passim. PubMed ID: 21424143
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Leptin-mediated changes in hepatic mitochondrial metabolism, structure, and protein levels.
    Singh A; Wirtz M; Parker N; Hogan M; Strahler J; Michailidis G; Schmidt S; Vidal-Puig A; Diano S; Andrews P; Brand MD; Friedman J
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):13100-5. PubMed ID: 19622746
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Physiological responses to leptin levels in lipodystrophy: a model for other hypoleptinemias?
    Rosenbaum M; Leibel RL
    J Clin Invest; 2018 Aug; 128(8):3237-3239. PubMed ID: 30010621
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Leptin restores markers of female fertility in lipodystrophy.
    Eifler L; Hoffmann A; Wagner IV; Klöting N; Sahlin L; Ebert T; Jessnitzer B; Lössner U; Stumvoll M; Söder O; Fasshauer M; Kralisch S
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3292-3297. PubMed ID: 30021121
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Update on Therapeutic Options in Lipodystrophy.
    Akinci B; Meral R; Oral EA
    Curr Diab Rep; 2018 Oct; 18(12):139. PubMed ID: 30370487
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
    Miehle K; Stumvoll M; Fasshauer M; Hierl T
    Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.